Other substances

SARS-CoV-2 Sclamp Vaccine

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

The candidate vaccine being developed by the University of Queensland/CSL/Seqirus is a molecular clamp stabilized Spike protein with MF59 adjuvant type of candidate vaccine. It is based on the Protein Subunit platform, which is also used for non-COVID-19 candidates, such as Nipah, influenza, Ebola, and Lassa. Currently, this COVID-19 candidate vaccine is in Phase I clinical trial. 

 

Supporting references

Link Tested on Impact factor Notes Publication date
Draft landscape of COVID-19 candidate vaccines
healthy adults Jul/28/2020

AI-suggested references

Link Publication date
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.
Apr/05/2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Apr/19/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04495933 A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults Active, not recruiting Phase 1 Jul/13/2020 Feb/02/2022
  • Alternative id - UQ-1-SARS-CoV-2-Sclamp|ACTRN12620000674932p
  • Interventions - Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Nucleus Network Brisbane (Q-Pharm Pty Ltd), Herston, Queensland, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 216
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Frequency of Solicited local reactogenicity adverse events (AEs)|Frequency of Solicited systemic reactogenicity adverse events (AEs)|Grading of Solicited local reactogenicity adverse events (AEs)|Grading of Solicited systemic reactogenicity adverse events (AEs)|Unsolicited adverse events (AEs)|Serious adverse events (SAEs), Medically attended adverse events (MAAEs) and any Adverse events (AEs) leading to study withdrawal at any time during the study|Geometric Mean Titer (GMT) of the serum antibody response|Geometric Mean Titer (GMT) of the serum neutralizing antibody (NAb) response to SARS-CoV-2 virus|Total serum antibody immune responses|proportion of participants with ≥ 4 fold increase in titer above baseline|GMT of the serum neutralizing antibody (NAb) titres
Export (.csv)